FDA considers allowing compounding pharmacies to produce BPC-157 and TB-500 peptides

The U.S. Food and Drug Administration is reviewing whether compounding pharmacies should be permitted to produce BPC-157, TB-500 and other peptides that were previously banned. The outcome could open legal access to these compounds for patients in the United States. No timeline or decision has been announced yet.